HomeSGX-LISTED COMPANIES

SGX-LISTED COMPANIES

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...
SGX-LISTED COMPANIES

Camsing Healthcare Retail Cuts Help Narrow Losses In Q1 FY2027

How a 30% Revenue Drop Actually Narrowed Losses The Singaporean health supplement market remains a...
SGX-LISTED COMPANIES

Why Lincotrade’s S$117 Million Record Order Book Could Be Just The Beginning

De-risking the Investment Lincotrade & Associates is aggressively securing a record backlog, the Group is...
SGX-LISTED COMPANIES

Autagco Funds Its Senior Care Pivot With New Capital In Q3 FY2026

4 Surprising Truths About Autagco’s Radical Shift Autagco Ltd has pivoted from health-focused culinary concepts...
SGX-LISTED COMPANIES

Salt Investments FY2026 Revenue Surges As Impairments Mask Growth

What Investors Need to Know About Salt Investments FY2026 Results The FY2026 results for Salt...
SGX-LISTED COMPANIES

Samurai 2K Aerosol FY2026 Profit Fueled By Fire Insurance Proceeds

Is Samurai 2K’s Post-Fire Recovery Operational or Artificial? Corporate resilience is often a matter of...
SGX-LISTED COMPANIES

Digilife Technologies Pivots From Telecom To Indian Concrete In FY2026

Digilife’s Radical S$20 Million Pivot For many equity investors, a corporate turnaround is a slow,...
SGX-LISTED COMPANIES

How AMOS Group Is Tackling Its FY2026 Revenue & Debt Challenges

A Calculated Contraction The FY2026 financial results for AMOS Group signal a "hard reset" rather...
SGX-LISTED COMPANIES

Zixin’s FY2026 Results Signal A Shift In Modern Agritech

Sweet Potatoes and Biotech The humble sweet potato is undergoing a high-tech transformation. What was...
SGX-LISTED COMPANIES

Vividthree Eyes Physical Venues To Rebound From FY2026 Revenue Slump

A 56% Revenue Collapse or a Ruthless Masterclass in Operational Efficiency? The digital media sector...
SGX-LISTED COMPANIES

Ley Choon FY2026 Revenue Grows While Profits Feel Cost Pressure

Why Revenue Growth Didn’t Lead to Profits for Ley Choon In the world of equity...
SGX-LISTED COMPANIES

Mary Chia Pivots To Digital & E-Commerce Following FY2026 Revenue Drop

Mary Chia’s 71% Revenue Collapse and the Digital Pivot For decades, Mary Chia Holdings Limited...
Load more

Latest articles

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...
Pharmaceutical

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...
Pharmaceutical

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

Keep exploring

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge in profit for the third quarter ended May 31, 2026. This performance marks a decisive shift from a period of recovery toward a new phase of resilient growth in the...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the country grapples with a growing burden of non-communicable diseases (NCDs), particularly diabetes and chronic kidney disease. Recent estimates show that one-in-six Malaysians has diabetes, while one-in-seven is at risk of chronic...

Keep exploring